Evidence map›Paper›PMID 39492580›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2024

[Application Research of Serum miR-4646-5p, miR-3654 Combined with Traditional Lung Cancer Tumor Markers in the Diagnosis of Lung Cancer in Xuanwei, Yunnan Province].

Renning Zhang, Xinrui Wan, Xuan Huang, Mingping Li, Kai Xu, Raohong Fang, Ya Li

Abstract readEnglish Abstract
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Renning ZhangDepartment of Clinical Laboratory Medicine, Yunnan Diannan Central Hospital (The First People's Hospital of Honghezhou), 
Mengzi 661100, China.
Xinrui WanDepartment of Clinical Laboratory Medicine, The Third People's Hospital of Kunming, Kunming 650301, China.
Xuan HuangDepartment of Clinical Laboratory Medicine, Yunnan Diannan Central Hospital (The First People's Hospital of Honghezhou), 
Mengzi 661100, China.
Mingping LiDepartment of Clinical Laboratory Medicine, Yunnan Diannan Central Hospital (The First People's Hospital of Honghezhou), 
Mengzi 661100, China.
Kai XuDepartment of Clinical Laboratory Medicine, Yunnan Diannan Central Hospital (The First People's Hospital of Honghezhou), 
Mengzi 661100, China.
Raohong FangDepartment of Clinical Laboratory Medicine, Yunnan Diannan Central Hospital (The First People's Hospital of Honghezhou), 
Mengzi 661100, China.
Ya LiDepartment of Clinical Laboratory Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence rate of lung cancer in Xuanwei has been continuously increasing in recent years, and it also features high incidence across all age groups and high mortality rates among female lung cancer patients. Therefore, the search for more stable biomarkers for the diagnosis of Xuanwei lung cancer holds tremendous clinical application prospects. This study aims to explore the clinical application value of these four microRNAs (miRNAs) individually and in combination with traditional lung cancer tumor markers in the detection and diagnosis of Xuanwei lung cancer.

methodsBy detecting the expression levels of four miRNAs and five traditional lung cancer tumor markers in the serum of 45 Xuanwei lung cancer patients and healthy physical examination participants, the Logistic regression model was employed to comprehensively evaluate the sensitivity, specificity, diagnostic efficacy, and other relevant statistical indicators of the four miRNAs in the diagnosis of Xuanwei lung cancer.

resultsAmong the individual miRNAs, miR-4646-5p and miR-3654 showed significant differences in expression levels between the Xuanwei lung cancer group and the control group (P<0.05). miR-3654 demonstrated the best diagnostic performance with a sensitivity of 86.7%, specificity of 82.2%, and an area under the curve of 0.847. Combining miR-3654 with miR-4646-5p and carcinoembryonic antigen (CEA) resulted in the highest diagnostic efficacy for Xuanwei lung cancer, with a sensitivity of 73.3%, specificity of 93.3%, area under the curve of 0.901, and a positive predictive value of 91.7%.

conclusionsAmong the four miRNAs, serum miR-3654 exhibits the best diagnostic efficacy for Xuanwei lung cancer. Combined with miR-4646-5p and CEA, its diagnostic value for Xuanwei lung cancer can be effectively enhanced, making it a promising screening indicator for Xuanwei lung cancer.

Indexed as

Biomarkers, TumorLung NeoplasmsMicroRNAsAdultAgedChinaFemaleHumansMaleMiddle AgedBiomarkers, TumorMicroRNAsDiagnostic efficacyLung neoplasmsmicroRNATumor markersXuanwei lung adenocarcinoma

Identifiers

PMID39492580
PMCPMC11534570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.